Recce Pharmaceuticals

Recce Pharmaceuticals P/TBV

The Price to Tangible Book Value (P/TBV) of Recce Pharmaceuticals (RCE.AX) as of Nov 4, 2026 is -10.38. In the previous year, Price to Tangible Book Value (P/TBV) was -56.85 — a change of -81.75% (higher).

P/TBV

-10.38

YoY

-81.75%

Last updated:

Price to Tangible Book Value (P/TBV) of Recce Pharmaceuticals is 2026 -10.38 . Price to Tangible Book Value (P/TBV) of Recce Pharmaceuticals was 2025 -56.85 . It decreases by -81.75% higher compared to the previous year.

The Recce Pharmaceuticals P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2019
-427.78 AUD
Jan 1, 2020
75.03 AUD
Jan 1, 2021
8.46 AUD
Jan 1, 2022
17.25 AUD
Jan 1, 2023
-67.02 AUD
Jan 1, 2024
-18.22 AUD
Jan 1, 2025
-56.85 AUD
Jan 1, 2026
-10.38 AUD
The Recce Pharmaceuticals P/TBV history
YEARP/TBVYoY
-10.38-81.75%
-56.85+212.05%
-18.22-72.82%
-67.02-488.65%
17.25+103.79%
8.46-88.72%
75.03-117.54%
-427.78-271.33%
249.69-15.08%
294.01+495.31%
49.39+34.15%
36.82-101.19%
-3,087.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Price to Tangible Book Value (P/TBV) of Recce Pharmaceuticals is -10.38 in 2026.

Price to Tangible Book Value (P/TBV) of Recce Pharmaceuticals changed from -56.85 to -10.38, representing a -81.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Recce Pharmaceuticals

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Recce Pharmaceuticals